Roles and clinical implications of N6-methyladenosine in digestive system tumors

IF 4.2 2区医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Mutation Research-Reviews in Mutation Research Pub Date : 2026-01-01 Epub Date: 2026-03-19 DOI:10.1016/j.mrrev.2026.108588

Shixin Luo , Lusheng Liu , Min Sun , Jianwei Wang , Fangyu Sui , Miao Zhang , Xinyu Wu , Miao Qu

{"title":"Roles and clinical implications of N6-methyladenosine in digestive system tumors","authors":"Shixin Luo , Lusheng Liu , Min Sun , Jianwei Wang , Fangyu Sui , Miao Zhang , Xinyu Wu , Miao Qu","doi":"10.1016/j.mrrev.2026.108588","DOIUrl":null,"url":null,"abstract":"<div><div>Digestive system tumors such as gastric, colorectal, esophageal, hepatocellular, pancreatic and gallbladder cancers are a huge global health burden, featuring high incidence, high malignancy, difficult early diagnosis and poor prognosis. Identifying novel diagnostic biomarkers and innovative therapeutic interventions has therefore become an urgent clinical need. N6-methyladenosine (m6A) RNA modification is the most prevalent epigenetic mark on eukaryotic mRNAs and plays a key and multifaceted regulatory control role in the pathobiology of a variety of digestive system malignancies mainly through its \"author\", \"eraser\" and \"reader\" proteins. Dysregulation of these m6A regulators and the resulting abnormal m6A are closely related to tumor development and treatment outcomes, M6A critically regulates the pathobiology and therapeutic effects of digestive cancers, and its regulators are expected to be biomarkers and therapeutic targets, and this review helps to guide the diagnosis, treatment and prevention of digestive system tumors in the future.</div></div>","PeriodicalId":49789,"journal":{"name":"Mutation Research-Reviews in Mutation Research","volume":"797 ","pages":"Article 108588"},"PeriodicalIF":4.2000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mutation Research-Reviews in Mutation Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1383574226000049","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Digestive system tumors such as gastric, colorectal, esophageal, hepatocellular, pancreatic and gallbladder cancers are a huge global health burden, featuring high incidence, high malignancy, difficult early diagnosis and poor prognosis. Identifying novel diagnostic biomarkers and innovative therapeutic interventions has therefore become an urgent clinical need. N6-methyladenosine (m6A) RNA modification is the most prevalent epigenetic mark on eukaryotic mRNAs and plays a key and multifaceted regulatory control role in the pathobiology of a variety of digestive system malignancies mainly through its "author", "eraser" and "reader" proteins. Dysregulation of these m6A regulators and the resulting abnormal m6A are closely related to tumor development and treatment outcomes, M6A critically regulates the pathobiology and therapeutic effects of digestive cancers, and its regulators are expected to be biomarkers and therapeutic targets, and this review helps to guide the diagnosis, treatment and prevention of digestive system tumors in the future.

查看原文本刊更多论文

n6 -甲基腺苷在消化系统肿瘤中的作用及临床意义。

胃癌、结直肠癌、食管癌、肝细胞癌、胰腺癌和胆囊癌等消化系统肿瘤是全球巨大的健康负担，具有发病率高、恶性程度高、早期诊断困难、预后差等特点。因此，确定新的诊断生物标志物和创新的治疗干预措施已成为迫切的临床需要。n6 -甲基腺苷（m6A） RNA修饰是真核生物mrna上最常见的表观遗传标记，主要通过其“作者”、“擦除者”和“读取者”蛋白在多种消化系统恶性肿瘤的病理生物学中起着关键的、多方面的调控作用。这些m6A调节因子的失调及其导致的m6A异常与肿瘤的发展和治疗结果密切相关，m6A对消化道肿瘤的病理生物学和治疗效果起着至关重要的调节作用，其调节因子有望成为生物标志物和治疗靶点，本文综述有助于指导未来消化道肿瘤的诊断、治疗和预防。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Mutation Research-Reviews in Mutation Research 生物-毒理学

CiteScore

12.20

自引率

1.90%

发文量

审稿时长

15.7 weeks

期刊介绍： The subject areas of Reviews in Mutation Research encompass the entire spectrum of the science of mutation research and its applications, with particular emphasis on the relationship between mutation and disease. Thus this section will cover advances in human genome research (including evolving technologies for mutation detection and functional genomics) with applications in clinical genetics, gene therapy and health risk assessment for environmental agents of concern.